Description
Adamas Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues. It has developed a portfolio of chrono-synchronous therapies to address chronic neurologic disorders. Its first product candidate is ADS-5102, a chrono-synchronous amantadine therapy, for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease (PD). It has completed Phase II proof-of-concept study of ADS-5102 in these patients. Its Phase III clinical program included three placebo-controlled trials: EASED, EASE LID and EASE LID 3. Its second product candidate is ADS-4101, an extended-release version of single-agent compound for the treatment of epilepsy (partial onset seizures).
Address
1900 Powell St Ste 750
EMERYVILLE, CA 94608-2437
United States
EMERYVILLE, CA 94608-2437
United States
Website
http://adamaspharma.comKey stats and ratios
| Q2 (Jun '17) | 2016 | |
| Net profit margin | -1037250.00% | -10499.65% |
| Operating margin | -1014450.00% | -10661.54% |
| EBITD margin | - | -10520.28% |
| Return on average assets | -59.77% | -44.29% |
| Return on average equity | -74.41% | -48.36% |
| Employees | 72 |
No comments:
Post a Comment